Elan

IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial

- Results show UVIDEM was well-tolerated with signs of durabledisease control in advanced melanoma patients - IRVINE, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- IDMPharma, Inc. today presented preliminary results from a Phase IIUVIDEM (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). Theresults showed that UVIDEM was well tolerated with evidence ofefficacy and induction of immune...

Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - SyntaPharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical companyfocused on discovering, developing, and commercializing smallmolecule drugs to treat severe medical conditions, today announcedencouraging results from the analysis of overall survival (OS) timefor patients in the Company's double-blind, randomized, controlled,multi-center...

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

Clinical Phase I and II data presented at American Society ofClinical Oncology (ASCO) 2007 Annual Meeting CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc.and Bristol-Myers Squibb Company today presented results frommultiple clinical studies of ipilimumab (MDX-010), aninvestigational immunotherapy, for patients with advanced melanoma.The results demonstrated an anti-tumor res...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

CHICAGO – June 2, 2007 – Long-term treatment withpegylated interferon alfa-2b in stage III melanoma had asignificant and sustained impact on relapse-free survival (RFS),according to the results of the largest adjuvant trial everconducted in patients with stage III melanoma. Results of the PhaseIII study, led by...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented preliminary data from a Phase 2monotherapy trial showing that tanespimycin demonstrated antitumoractivity and tolerability in patients with metastatic melanoma,including one patient with a BRAF mutation (V600E) who had failedprior chemotherapy (within 6 weeks of initiation) and while ontanesp...

SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial

-- Data Presented at Annual Meeting of the American Society ofClinical Oncology -- SAN MATEO, Calif. -- June 4, 2007 -- SciClone Pharmaceuticals,Inc. (Nasdaq:SCLN) and Sigma-Tau S.p.A today announced thatSciClone's lead product candidate thymalfasin (ZADAXIN(r), thymosinalpha 1) achieved its primary endpoint in a phase 2 clinical trialtreating patients diagnosed with stage IV malig...

Inovio Biomedical's DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results

SAN DIEGO--(BUSINESS WIRE)--May 24, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA-based DNAvaccines for cancers and infectious diseases and a novelalternative to surgery to treat localized cancers, announced todaythat interim clinical trial results demonstrated that a DNA-basedimmunotherapy delivered by Inovio's electroporation technology wassafe and tole...

Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide

CRANBURY, N.J., and BRISTOL, Tenn., May 22, 2007/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and KingPharmaceuticals, Inc. reported today that data from Study 16 andStudy 17 of the Phase 2B clinical trial program evaluatingbremelanotide in men with erectile dysfunction (ED) were presentedyesterday at the American Urological Association (AUA) AnnualMeeting (AUA 2007) held in Anahe...

Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction

CRANBURY, N.J. and BRISTOL, Tenn., May 09, 2007/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and KingPharmaceuticals, Inc. today announced plans to present the resultsfrom two bremelanotide Phase 2b studies of men with erectiledysfunction (ED). The presenters are Jed Kaminetsky, MD, ClinicalAssistant Professor, Department of Urology, NYU School of Medicine;Stanley E. Althof, PhD,...

Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published

PLANTATION, Fla., May 08, 2007 /PRNewswire-FirstCall/ --Viragen, Inc. and Viragen International, Inc. today announcedresults from a sponsored in vitro study conducted at UmeaUniversity in Sweden, which found that Multiferon(R) (multi-subtype, human alpha interferon) suppressed development ofresistant human melanoma clones to a far greater degree thanrecombinant alpha interferon. The stud...

Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival Benefits as Mitigator Against Radiation-Induced Damage in Study

Chief Scientist to Present Results at 2007 American Association forCancer Research Annual Meeting CLEVELAND, April 09, 2007 /PRNewswire-FirstCall/ -- ClevelandBioLabs, Inc. , announced today the results of its study ofProtectan CBLB502's efficacy as a mitigator of bothgastrointestinal (GI) and hematopoietic (bone marrow/bloodproduction) radiation-induced damage in non-human primates. The...

Cholesterol Drug Fails to Slow Progression of Coronary Disease, Cleveland Clinic Study Reports

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- Cleveland Clinicresearchers today report that the drug torcetrapib, despite raisinghigh density lipoprotein cholesterol (HDL) or the "good"cholesterol by more than 60%, did not slow the progression ofplaque buildup in the coronary arteries as measured using anultrasound probe. Steven Nissen, M.D., Chairman of Cardiovascular Medicine atCl...